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Abstract 
Oncologists need to recognise the need to move beyond the ECOG Performance Status 
score (ECOG PS).  ECOG PS is a longstanding and ubiquitous feature of oncology. It was 
evolved 40 years ago as an adaption of the 70-year-old Karnofsky score. It is short, easily 
understood and part of the global language of oncology. The wide prevalence of ECOG PS 
attests to its proven utility and worth to help triage patient treatment. 
The ECOG PS is problematic. It is a unidimensional functional score. It is mostly physician 
assessed, subjective and therefore open to bias. It fails to account for multimorbidity, frailty 
or cognition. Too often the PS is recorded only once in wilful ignorance of a patient’s 
changing physical state. 
As modern oncology offers an ever-widening array of therapies that are ‘personalised’ to 
tumour genotype modern oncologists must strive to better define patient phenotype. 
Using a wider range of scoring and assessment tools oncologists can identify deficits which 
may either be reversed or steps taken to mitigate detrimental effects of treatment. These 
tools can function well to identify those patients who would benefit from comprehensive 
assessment.  This article identifies the strengths of PS but highlights the weaknesses and 
where these are supported by other measures. A strong recommendation is made here to 
move to routine use of the Clinical Frailty Score to start to triage patients and most 






The safe and effective practice of oncology asks of us that we classify the cancer using 
appropriate tools. We must then assess the treatment options in the context of the 
patient’s ability to tolerate them. Achieving the optimum therapeutic ratio requires that our 
patient fitness meets a threshold. The long-established shorthand for that fitness has been 
the ECOG Performance Status (PS); a synthesised scale of symptoms and mobility. The ECOG 
has been around for a long time, its development from the 70 year-old Karnofsky score 
(KPS)  [1] is summarised in a single paragraph of less than 50 words from a paper written 40 
years ago [2] which describes how the percentage based Karnofsky was further simplified 
into a five point scale.  
In those intervening decades the ECOG PS has become the common and international 
language of oncology practice allowing a swift shorthand which is shared between teams 




There is much to recommend the ECOG PS and its’ impressive longevity attests to a broad 
utility. The simplicity of a six-point scale has assisted its ubiquity. When compared directly 
with KPS  (a meta-analysis of studies where HCPs completed both assessments) KPS may 
perform better [3] although the 5 point simplicity of the ECOG-PS may be easier for patients 
to understand and HCPs to remember. That same simplicity contributes to low 
interobserver variability [4] and agreement between members of the multidisciplinary team 
[5]. The scale can also be completed by patients themselves with high physician 
concordance in reporting their functional status [6, 7]. In the modern era ECOG PS recording 
can also be done effectively and accurately with wearable technologies [8].  
 
The ECOG PS has gone on to prove both prognostic and predictive utility. The score has 
shown to align closely to benefit in the use of cytotoxic chemotherapy in lung cancer [9] and 
in that context strongly influences treatment decisions in lung cancer chemotherapy [10]. It 
helps prognosticate in a palliative care setting [11] and can predict for depression [12] . 
ECOG PS is widely used in UK oncology and in an recent survey 90% of healthcare 
professionals managing older patients with cancer used it as part of their assessment [13]. 
The primacy of ECOG PS is such that it would be rare to see peer reviewed research in print 
which did not report the score of treated cohorts. It is also used widely in regulatory 
frameworks and guidance. In the UK it used to filter funding for novel cancer therapies. As 
of March 2020, there are 44 unique drugs (supporting 64 indications for solid tumours) on 
the NHS England Cancer Drug Fund list. All but two of have strictures around ECOG PS that 
limit prescribing (three requiring “sufficient PS”, 14 requiring a PS of at least 2 and the 
remainder needing the patient to demonstrate a PS of 0 or 1). There are no other indicators 
of fitness required in any of the listings [14]. The Cancer Drug Fund list is dominated by 
drugs of eye-watering cost and in that context it may be surprising that the only functional 
assessment required of the patient before prescribing is a 5 point scale. 
 
Given this prevalence of ECOG PS in cancer a curious aspect is that it has not been more 
widely adopted outside of oncology, apart from some very limited early uptake in renal and 
geriatric medicine; as an assessment of function, it has predictive mortality in older adult 





Problems with PS 
 
Although ECOG PS use is widespread it is still far from universal. There are still a substantial 
number of clinicians who will make a decision to use chemotherapy despite poor PS [10]. 
ECOG PS often does not reach the multidisciplinary team meeting where treatment 
decisions are discussed; in a recent study of UK practice only 14% of such discussions 
included information about patient fitness [16]. This may not be a problem with the scale as 
much as a problem of the team not recognising the need for functional assessment. 
 
Despite the long pedigree of PS it has significant problems. The useful simplicity of the ECOG 
PS also is one of its’ major drawbacks. It lacks granularity, particularly around the (often 
crucial) decision nexus at Performance Status 2. The score contains no weighting as to 
whether the impairment in function is musculoskeletal or due to organ dysfunction (e.g. 
cardiac or respiratory). The PS lacks any dimension to assess the impact of cognition or 
mood and no heed of patient social status or attitudes. Consider the cases of two men with 
the same diagnosis and ECOG PS but with widely different physical reserve, functional 
capability and medical histories (See FIG 1.) It would not surprise oncology professionals if 
these two patients had very different experiences with cancer therapy despite having the 
same ECOG PS score. 
Everyday usage of ECOG PS assumes that the risk-benefit ratio of a given treatment will 
change according to the points on the scale, with caution required with higher scores due to 
higher risk. There is a paucity of evidence to support differential outcomes according to 
ECOG PS and the exclusion of patients of poor PS means that subgroup analysis is usually 
not possible. When ECOG PS is reported in clinical trial work it is most often as a clinical 
feature of the cohorts and occasionally  as a variate in terms of benefit; it is only rarely 
reported as a variate with respect to toxicity. A meta-analysis of over 100 RCTs showed that 
whilst 60% reported PS subgroups for analysis of efficacy none did so for toxicity. This does 





There are other problems too; the score  is  (predominantly) physician assessed and 
therefore subjective and prone to bias [18]. It may vary according to the quality of history 
taken/provided. Vignette studies have shown discrepant PS scoring between healthcare 
professionals was significantly influenced by the provided background social information 
with these differences most obvious in the decision threshold region around a PS score of 2 
[19]. Overestimation of PS is not uncommon and when there is discordance between 
patient and physician over scoring it associated with poorer prognosis in both solid tumours 
[7, 20, 21]  and in haematological  malignancies  [22]  In a UK lung clinic physician assessed 
PS had poor predictive ability for whether or not a patient would complete planned 
treatment (although patient self-rated PS was more usefully predictive) [23].  
Working with patients to design the best treatment course relates directly to how 
physicians make decisions. Decision making will be influenced by contextual factors (the 
environment in which the decision is made), decision-maker related characteristics (the 
biases and behaviours of the decision maker as a person) and decision specific elements 
(the nature of the decision itself) [24] . The impression of a patient’s functional status may 
be formed differently according to context and interpreted differently according to decision 
maker behaviours. How that functional status assessment is implemented may depend on 
decision specific elements. All of these elements are too vulnerable to biases and variation 
in estimate if we rely on a tool as basic and subjective as ECOG PS. As we grow our evidence 
base this too needs to be supported by a greater granularity in understanding treatment 
effects according to functional status.  
 
There have been attempts to refine and improve the ECOG PS.  The Palliative Performance 
Scale which includes assessments of self-care, nutritional intake and conscious level [25] 
shows utility in prognosticating towards end of life . The Palliative Prognostic Index (PPI) 
utilizes the PPS, oral intake, dyspnoea at rest, and delirium to predict 3-week and 6-week 
survival. The Palliative Prognostic (PaP) Score uses clinical prediction of survival, KPS, 
anorexia, dyspnoea and white cell metrics to predict 30-day survival in patients with 
advanced cancers [26]. A further adaptation accounts for delirium [27]. Here the ECOG PS 
score has mutated in purpose from predicting fitness for treatment to preparedness for end 
of life but it is recognised that PS is recorded to a lesser degree once initial treatment has 
been determined and even less so as a patient progresses through advanced stage of 
disease into palliative care  [28]. In palliative radiotherapy scores have been developed that 
use other factors (including site of metastasis, previous radiotherapy, tumour type) added 
to the ECOG PS or KPS ) to produce a score that may assist in identifying with those most 
likely to benefit from the treatment (Chow Score) [29, 30]. These scores have been adapted 
because of the limitations of the performance score and all have some proven utility in the 
specific scenarios for which they have been developed. Adapted performance scores do not 
help us fulfil a brief for a tool that provides valuable information across the wider spectrum 
of all cancer diagnoses, stages and treatments. 
Changing Paradigms 
 
When Karnofsky and Burchenal designed their original performance score in 1949 it was as 
part of a textbook for the nascent science of chemotherapy. Chemotherapy has changed 
significantly since then and is far from the only therapeutic paradigm in regular usage. 
Immunotherapy, radiotherapy and surgical oncology trials have all adopted ECOG PS as a 
routine baseline assessment. These developing modalities may demand less (or more) of 
patient fitness. Immunotherapy in particular is a treatment that can appear well tolerated 
unless toxicities develop. The evolution of toxicity appears independent of performance 
status. This has led to critical reviews of the ECOG PS as a triage tool for immunotherapies, 
particularly in lung cancer where many patients are assessed as PS 2 or lower at 
presentation. Meta-analyses of immunotherapy have shown similar overall survival gains 
regardless of PS [31, 32] although they are problematic as they take data from trials which 
included only small numbers of patients of poor PS  [33]. Also trials of immunotherapy may 
show similar ORR benefits regardless of PS but this may not be enough to overcome the 
survival disadvantage of poor PS at the outset [34]. There are also signals that despite the 
overall survival gains in lung cancer immunotherapy appearing to be agnostic of patient PS 
this may not be true for all subgroups. This may be particularly the case in older patients 
where some outcomes still appear to be driven by poor PS (despite immunotherapy) [35]. 







It is not only treatment options that are evolving; populations are shifting too. 
As our populations age and our control of chronic diseases improve, we increasingly deal 
with the patient with multimorbidities and polypharmacy. Our current systems have 
evolved around single specialities which are a poor fit for the patient with multi-morbidities. 
The concept of multi-speciality “Cluster Medicine” [36] has been proposed but, as yet, 
oncology seems poorly prepared to adopt this model as training and practice and continue 
to enshrine specialism over generalism. It is in our current era of the older patient and the 
patient with multimorbidity that the ECOG PS is shown to be most deficient.   
One important way to move beyond performance status is to look instead at frailty. Frailty is 
a multidimensional concept that will encompass many of the issues that also inform 
Performance Status. Frailty is variably defined but recognises that an individual may not be 
able to recover to their functional baseline if physically stressed and is a consequence of 
cumulative decline in many physiological systems [37].  
 
It is crucial to understand that multimorbidity, age and frailty are independent; a patient 
may be older but not frail, have multimorbidities and not be older. Frailty and 
multimorbidity will overlap [38]. Clinicians will normally intuitively understand that not all 
older patients are unfit and that ageing and multimorbidity are not universally entwined. 
What matters is not the enumeration of calendar years or past diagnoses but a focused 
assessment of fitness. Frailty is likely to be a more helpful term for use by cancer 
multidisciplinary teams than age as it more specifically focuses on what a patient with 
cancer is likely to be able to tolerate when receiving treatment. 
 
Beyond Performance Status 
Performance status is a reductive assessment of function but there are multiple ways to 
enhance this to provide more granular analysis. To tailor therapy most effectively for the 
potentially frail patient we need to look beyond performance status and explore the 
domains of health characterised in Table 2. We may at the very least ask that ECOG PS be 
combined with some other scales of physical performance and ability that would give a less 
one-dimensional view of the patient’s ability and function.  
ECOG PS also gives a ‘label’ for a patient with no suggestion that there may be room for 
optimisation or reversibility. To work better, our scores need to identify patients who will 
benefit from treatment and also identify those that will not whilst predicting complications. 
It should be sensitive enough to be able to detect issues not found by routine history and 
physical examination in the initial evaluation. It should take account of geriatric syndromes 
and problems (delirium, falls, pressure ulcers, constipation) as well as smoking, alcohol 
excess, vision problems, social isolation and loneliness 
Reviews that address polypharmacy with subsequent medical optimisation may well 
improve functional status - such as optimisation of hypothyroidism or reduction in opiates. 
Frailty is a dynamic state which can improve with intervention;  pre frailty can respond to 
exercise, calorie review, protein diet and vitamin D supplementation [39]. The simple act of 
combining a geriatric screening tool such as the G8 will improve the utility of the PS  [40] 
One simple triage test would be to use an ECOG PS 2 or higher to trigger a next level of 
assessment –to focus on the true significance of any deficit to function (and whether there 
is reversibility). A list of useful tools for each of the domains under consideration is given in 
Table 2  
A significant problem with the ECOG PS is that it does not allow well to adjust for functional 
difficulties that predate the cancer. A careful history of ability to complete the basic skills of 
self-care as activities of daily living (ADLs) should be standard. The instrumental activities of 
daily living (IADLs) are those which are required to maintain independence e.g. shopping, 
laundry, paying bills and using the telephone/internet. ADLs/ IADLs will broadly correlate 
with ECOG PS and share similar characteristics in being able to identify poorer prognosis 
[41]. Nonetheless the IADL/ADL history should be an indispensable part of placing the 
patient in a domestic and societal context. Other functional scores include The Barthel index 
(BI). The ASA used by surgical colleagues gives information which performs similarly well 
[42] as does the Edmonton Frail Scale which has been recommended in the elective surgical 
setting [43].  
It is important to acknowledge that for many healthcare professionals scoring systems are 
not always popular. Although awareness of scoring systems was relatively high amongst UK 
cancer professionals there has been little enthusiasm to use them [13]. One might speculate 
that a score is antithetical to a clinician’s belief in the ‘art’ of diagnostic medicine. Whatever 
the reason for clinician’s dislike of scoring systems studies which demonstrate utility would 
hopefully become persuasive. 
An improvement on performance status scoring would be a scale that would allow for 
greater granularity than ECOG PS and would account for cognitive issues.  
 
 
Physical functioning may be more objectively assessed in the clinic. A comprehensive 
number of tests are available but the need for a shorthand in clinic has long been 
recognised. Assessment of function may be performed in a number of brief physical tasks; 
these include measures of hand grip strength [44] or gait speed [45]. One in three patients 
with slow gait speed will be frail. Physical tests can be combined with a brief timed element 
for greater differential estimations, these include 2-Minute Step Test, 30-Second Sit to 
Stand, Timed Arm Curl, and the Timed Up and Go [46]. All of these tests may be conducted 
relatively quickly in any normal clinic scenario and (with the exception of grip strength) 
without specialist equipment. The names of the tests themselves indicate that they can be 
performed in seconds or minutes. The ability to have these tests available is not limited by 
equipment, space or time but by the willingness of the clinical team to accept them as 
useful. Tests may be combined to increase the range of function tested e.g. the Short 
Physical Performance Battery measures a patient's gait speed, balance and timed sit‐to‐
stand the test has a high predictive power in identifying patients most likely to complete 
chemo , overall prognosis and physical decline [23, 47, 48]. Physical functioning may be 
combined with short functional questions; the PRISMA 7 questionnaire is a simple seven 
item questionnaire to identify disability, has been used in earlier frailty studies and is also 
suitable for postal completion. (and may be combined with TUG or gait speed for improved 
accuracy) [49] 
A review of all the available tools  to assess and quantify frailty and its’ domains is beyond 
the scope of this article and has been comprehensively performed by other authors [50-52]. 
The modern oncologist needs to have insight into these tools and understand when and 
where they should be effectively deployed in screening their patients. 
 
These tests do not take a long time; validation studies  show that screening tests can be 
completed in less than half an hour with two thirds of that time spent by patient or 
caregiver in completing tests and 5-6 minutes required by the healthcare provider [53-55].  
When we compare this with the amount of time that the patient will spend on diagnostic 
testing prior to treatment or the costs of that treatment itself claiming that there is “no 
time” to complete functional assessments begins to look indefensible [56]. Baseline 
echocardiography, DPD deficiency testing or renal function assessment may all be part of 
routine protocol in chemotherapy delivery alongside complex and expensive imaging 
technology in staging. Adding more detailed functional and frailty assessment should be 
considered similarly necessary.   
For therapies that carry low burden or for patients who are fit then ECOG PS continues to be 
an adequate basic assessment. In many of these cases an ECOG PS will tell the treating team 
enough to know that it is reasonable to proceed with standard of care. Accepting that PS 
has a ‘green light’ function also commits us to accept that it may also point to amber or red  
and in these situations, a further detailed review is required. That review may best take the 
form of a comprehensive assessment – most often seen in older adults as a Comprehensive 
Geriatric Assessment or CGA. A CGA is not a score or a number, but a multi-disciplinary 
process that identifies medical, psychosocial, and functional limitations of a frail person 
which then leads to a coordinated plan to maximise potential for health and tackle 
reversible issues [57, 58]. In contrast to the scores described here a CGA is a process and 
intervention rather than a simple enumeration of potential issues. A fuller assessment using 
the domains that ae regular part of a CGA are likely to identify issues that are also routinely 
detected in a PS. For an assessment to have a beneficial purpose it must identify reversible 
elements of frailty particularly those that are likely to influence treatment decisions.  A 
Comprehensive Geriatric Assessment therefore becomes a valid use of resources when it 
may meaningfully influence the oncology decision at hand.  
It is not surprising that in such a detailed process an adequate PS may hide problems which 
can be identified by CGA [59].  These benefits of CGA would seem obvious and international 
guidance for management of older cancer patients recommends the process as a standard 
[52] [60]  [61] .  
In the UK however only 15% of UK oncology healthcare professionals included geriatricians 
in care of patients “often or always” [13] and with very significant workforce issues greater 
demand for CGA may quickly outstrip supply [62]. It is not likely to be possible anytime soon 
to offer comprehensive assessment for all. Under these circumstances it is reasonable to 
propose ECOG PS as permissive for fitter, younger patients and to use more instructive tools 
and scores to identify and triage those who may benefit from a comprehensive assessment. 
When CGA is not accessible, practical or possible the simple example of adding a G8 to 
baseline assessment still improve prognostic certainty and allow for better and safer triage 
of patients [63] 
 
PS is an observed scale of function; it was not intended to reflect on patient reported 
outcomes. Although PS can correlate with Quality of Life [64] it was not designed to do so, 
quality of life measures however can, if correctly recorded, give valuable information 
around function and outcome. Patients reporting PROMS can outperform ECOG PS as a 
predictor of survival as can a formal assessment of quality of life  [18, 65, 66] . In older 
patients incorporating a patient reported tool like the Vulnerable Elders survey as part of 
the early assessment would be helpful- a simple screening tool that can be administered by 
non-medical personnel in approximately 4 minutes in person or over the telephone 







Tools and Calculators 
Extra information gathered as part of a comprehensive assessment or as part of a scoring 
system needs to be more than a proforma version of a thorough history and examination. 
Oncologists should be persuaded that these data allow for more better definition of the 
patient within the population but moreover assists shared decision making.  There are well 
validated tools available to oncologists to incorporate features of functional and physical 
assessment into clinical decision making. The CARG and CRASH tools have been developed 
to assist higher quality decision making in treating (specifically) older adults. The validation 
set of the CARG tool was able to predict chemotherapy toxicities for older adults in a way 
that the KPS was not. The CARG tool has been shown to be practical in application outside 
of a research setting [68]  [69]. The models are built to be used in a clinical environment and 
can enrich a consent procedure and shared decision making with the patient by 




The Clinical Frailty Score (developed in Canada by Dr Kenneth Rockwood and team and 
often named after him) improves on Performance status [72] but like the ECOG scale 
broadly relies on the core skills of clinical history taking and examination. The CFS provides 
greater differentiation than the ECOG PS.  It is intended that the CFS be used alongside 
formal clinical assessment and (ideally) a comprehensive geriatric assessment. It would not 
be appropriate to define frailty solely on a CFS of 7 or higher without a formal clinical 
assessment [73]. The CFS is also not validated in patients under the age of 65. Whilst CFS 
represents an improvement on ECOG PS it should be seen as part of a continuum towards 
fuller assessment. It is not validated for measuring improvement in individuals after an 
acute illness for example. In a perfect world the CFS may be seen as a conclusion to a 
patient focused work up including many of the tools described above, triggered by a PS of 
>= 2. This needs to be done with the aim of improving the patient’s current situation or 
tackling reversible elements of frailty that may permit oncological treatment – in this 
context a CGA becomes an oncological Geriatric Assessment. The CFS was never designed ot 
intended to be an upgrade of ECOG PS but it certainly has benefits. Perhaps the greatest 
advantage of the CFS is its’ widespread use in secondary care. It has been widely adopted 
throughout acute and emergency medicine in England. The CFS can be used quickly and 
easily and as a tool, proven to be useable within one minute, was acceptable for use by 75% 
of emergency department staff in a UK study [74]. Because of the utility of the CFS it has 
been proposed by NHS England as the preferred triage and assessment tool across the NHS 
during the Covid-19 pandemic [75]. The CFS has therefore become a tool for recognising 
frailty using a language that is shared not just within geriatrics or oncology but throughout 
the hospital ecosystem. This shared language of frailty already gives the CFS an advantage 
over the ECOG PS – a codified language only spoken and understood within oncology. 
Recognition of the utility of the CFS in cancer practice has led to the recommendations in 
the UK that the score recorded as part of standard practice in older women with breast 







Clinical teams should understand that incorporating almost any form of fitness assessment 
is going to build on the reductive scoring of the ECOG PS. This assessment will require time 
and workforce to implement correctly. Some of these assessments may take several 
minutes and a battery of assessments may take up to an hour. A few of these assessments 
(but not all) would prompt further onward referral for CGA. This should not be positioned as 
an unreasonable demand as prelude to a treatment that impacts future morbidity and 
mortality for that patient. We need to move beyond considering these assessments so of 
function and functional reserve as desirable and to accept them as essential 
 
In an era that promises truly personalised medicine it is no longer appropriate to assess and 
record patient fitness for treatment with an overly simplified unidimensional tool such as 
ECOG PS. We cannot make claim to be delivering holistic care with such a limited 
assessment.  Modern oncology is asking way too much of ECOG PS to profile our patients, 
however the leap to a full Comprehensive (Geriatric) Assessment is asking way too much of 
our system which lacks the time, resource and expertise required.  
 
Moving to record dimensions of frailty, multimorbidity and functional status should become 
part of standard clinical and research practice. Usages of these tool will allow for better 
consent process. This is likely to be of greatest utility in those patients of PS2 and 3 where 
the scale provides less granular information. 
Oncology teams should familiarise themselves with the domains of frailty and how they are 
scored and assessed. In collaboration with their colleagues in elderly care and 
Prehabilitation and rehabilitation professionals formalised assessment should be a part of 
triaged intervention to optimise fitness and assist the frail. 
As clinicians we need to understand what reserve or capacity the patient in front of us has 
for treatment. Population based statistics can guide us, but we must also understand that 
there are no ‘magic numbers’ or scores. What is required is focused use of the tools 
described above combined with expert and multidisciplinary judgement.  
To manage frailty successfully we need a shared language to be communicate across 
professional groups and within scientific publication. The Clinical Frailty Score has already 
embedded across secondary care and shown validity in cancer populations and is 
recommended here for cancer professionals to adopt more widely. 
The Clinical Frailty Scale provides a means for oncologists to move beyond the limiting 
confines of the PS, too long a solely a measure for cancer, and share language with the rest 
of the hospital in discussing and measuring frailty. Performance Status has served us well 
but a modern paradigm demands more precision in all aspects of our care – especially 
evaluation of our patients. 
We have an obligation to find the best treatment option for individual patients but also to 
report and record our outcomes accurately. Spending time making fuller assessment of the 
patient around the domains of multimorbidity, ageing and frailty is time well spent and is 
minimal in comparison to the time spent by patients on treatment and by teams in 




   
Table 1 : Domains and How they may be assessed 
 
   
Functional Status  ADLS 
IADLS 





MOB-T (for fatigue) 




Short Physical Performance Battery 
Hand Grip Test 
Falls history 
Psychological health  Geriatric depression score 
Patient Health Questionnaire PHQ-9 
HADS 
NCCN Distress Thermometer 
Mental Health Inventory 
Multimorbidity  ACE 27 
Charlson Comorbidity Index (CCI) 
Klabunde adaptation of the CCI for cancer 
patients 
Cumulative Illness Rating Scale 
Cognition  MMSE 
MoCA (more sensitive tool for mild cognitive 
impairment) [78] 
Blessed Orientation Memory Concentration 
Mini-COG 
Clock drawing test 
Polypharmacy  STOP/START 




Groningen Frailty Score 






Well-dressed patient brought to clinic by family  
 Patient 1 Patient 2 
 75 year old males recently diagnosed with lung cancer. The 
first patient has been short of breath in the months leading 
to his diagnosis 
Functional Status Independent Needing help with shopping 
Recent fall 
 
Co-Morbidity Nil significant Diabetes 
Hypertension 
Ischaemic Heart Disease 
Polypharmacy Takes a statin 5 medications 
Nutrition BMI 29 BM1 19 
Recent weight loss of more 
3Kg 
Loss of appetite 
Cognition No issues Recently more forgetful 
Social Status Attends clinic with wife and 
daughter 
Widower who lives alone 
G8 Score 16 5 
CFS (Rockwood) 3 (Managing well) 6 (Moderately frail) 




Both patients could correctly be assigned a Performance status of 2 but we would expect 
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